Search results
Showing 16 to 30 of 61 results for warfarin
This guideline covers the assessment for and management of blood transfusions in adults, young people and children over 1 year old. It covers the general principles of blood transfusion, but does not make recommendations relating to specific conditions.
Idiopathic pulmonary fibrosis in adults: diagnosis and management (CG163)
This guideline covers diagnosing and managing idiopathic pulmonary fibrosis in people aged 18 and over. It aims to improve the quality of life for people with idiopathic pulmonary fibrosis by helping healthcare professionals to diagnose the condition and provide effective symptom management.
mobile or landline number and are asked to enter their INR reading, current warfarin dose, and have to answer 3 questions around...
TA157, TA249, TA327 for NOACs prescribing NG5, CG100, KTT16, QS93 for Warfarin NG5, NG106, CH180 for Amiodarone NG5, CG185, CG192, QS95...
Safe and effective management of stroke prevention in atrial fibrillation
treated with Warfarin and 701 with a direct oral anticoagulant (DOAC). Data published by INR star in 2016 demonstrated that 23.8% of...
Utilising the skills of the clinical pharmacist within the MDT for improved medicines optimisation
interventions Patient due for discharge who had not received their usual warfarin during admission. Medicines reconciliation completed....
Depression in adults with a chronic physical health problem: recognition and management (CG91)
This guideline covers identifying, treating and managing depression in people aged 18 and over who also have a chronic physical health problem such as cancer, heart disease or diabetes. It aims to improve the care of people with a long-term physical health problem, which can cause or exacerbate depression. This has the potential to increase their quality of life and life expectancy.
NICE has developed a medtech innovation briefing (MIB) on microINR for anticoagulation therapy .
Evidence-based recommendations on the CoaguChek XS system for self-monitoring coagulation status in adults and children. The recommendations originally included the InRatio2 PT/INR, but this was withdrawn from the market in October 2016 and is not currently available
Reversal of the anticoagulant effect of dabigatran: idarucizumab (ESNM73)
Summary of the evidence on idarucizumab for reversing the anticoagulant effect of dabigtatran to inform local NHS planning and decision-making
Find out more about the progress made in implementing NICE guidance on cardiovascular disease prevention
Evidence-based recommendations on percutaneous occlusion of the left atrial appendage in non-valvular atrial fibrillation for the prevention of thromboembolism. This involves using a special device to block the mouth of the left atrial appendage and stop the blood clot from getting into the bloodstream.
View recommendations for IPG349Show all sections
Sections for IPG349
Developing a medications policy and procedures for use in social care
Standard QS171. The policy covers all oral medication, transdermal patches, warfarin, insulin, topicals, subcutaneous anti-coagulants,...
Evidence-based recommendations on lenalidomide (Revlimid) for treating multiple myeloma in adults who have had at least 2 prior therapies.
Stroke and transient ischaemic attack in over 16s: diagnosis and initial management (NG128)
This guideline covers interventions in the acute stage of a stroke or transient ischaemic attack (TIA). It offers the best clinical advice on the diagnosis and acute management of stroke and TIA in the 48 hours after onset of symptoms.